Sansure Biotech Inc. achieved a record high in net profit after deducting non-recurring items in 2024, but the gross margin of diagnostic instruments saw a significant decline.

① The company achieved a revenue of 1.458 billion yuan for the year, a year-on-year increase of 44.78%; the net income excluding non-recurring items was 0.202 billion yuan, a significant year-on-year increase of 182.25%; the net income attributable to the parent company was 0.276 billion yuan, a year-on-year decrease of 24.23%; ② Revenue from diagnostic instruments has significantly declined, with a gross margin that is negative, mainly due to intensified market competition and rising costs.

cls.cnApr 28 21:28 ET

Micro-Tech's performance in 2024 remains stable, driven by the growth in endoscopy and tumor intervention business.

① The company achieved revenue of 2.755 billion yuan for the entire year, a year-on-year increase of 14.26%; net income attributable to shareholders was 0.553 billion yuan, a year-on-year increase of 13.85%; the non-recurring net income was 0.544 billion yuan, with a year-on-year growth rate of 17.48%. ② The high incidence of gastrointestinal cancer has driven the demand for endoscopic diagnostic equipment, while early diagnosis and treatment policies for cancer have further enhanced market potential.

cls.cnApr 28 21:26 ET

Shenzhen Mindray Bio-Medical Electronics' Q1 revenue decreased by 12.12% year-on-year, and Net income decreased by 16.81% year-on-year | Earnings Reports Insights.

More news is being continuously updated.

wallstreetcnApr 28 12:31 ET

United Imaging Medical: In Q1 2025, the non-recurring Net income increased significantly by 26.09%, and the investment in research and development continues to ramp up to enhance competitiveness.

In Q1 2025, United Imaging Medical's net income after deducting non-recurring items surged by 26.09%, with ongoing increases in R&D investment to enhance the industry's competitiveness. Key points include steady revenue growth...

wallstreetcnApr 28 05:04 ET

Touchstone International Medical Science Co., Ltd. Q1 non-recurring net profit slightly increased by 0.5%, with the endoscopic stapler still being "dominant".

① Benefiting from the market share increase brought by centralized procurement, Touchstone International Medical Science Co., Ltd. has maintained stable growth over the past four years, with a net income of 0.047 billion yuan in 2024, a year-on-year increase of 24.46%; ② Currently, Touchstone International Medical Science Co., Ltd.'s main business still focuses on staplers, and the product structure remains relatively simple. In 2024, over 70% of revenue comes from endoscopic stapler products.

cls.cnApr 27 19:37 ET

Direct coverage of the Star medical instruments industry collective Earnings Conference: Multiple companies are laying out AI medical Business, and key segments in innovation fields may accelerate the development of domestic production.

① Attending companies believe that tariff policies will bring some cost pressures and market challenges to enterprises, but at the same time, it has accelerated the localization process in relevant fields; ② Some attending companies disclosed the latest developments in their Business during the earnings briefing and the planning for related lines by 2025.

cls.cnApr 26 01:45 ET